Kite, a Gilead Company , presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback